EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Comparison of Cefuroxime‐Based Dual Therapy With Quadruple Therapy in Helicobacter pylori ‐Infected Treatment‐Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial

Ji-Yan Li iD, Ji-Chun Song, Xia Tian, Yun-Hua Liu, Xiang-Wu Ding, Ya Lin, Zhen-Yu Zhang iD, Hai Zhang, De-Min Li, Xiao-Wei Huang, Yun-Lian Hu, Li Li und 3 weitere

Helicobacter · 2025

DOI: 10.1111/hel.70037 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2025. Verfasst von Ji-Yan Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Anti-Bacterial Agents, Helicobacter pylori, Cefuroxime. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Tongji Hospital Clinical Research Fund, Natural Science Foundation of Hainan Province, Hainan Province Science and Technology Special Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High‐Dose Dual Therapy With Amoxicillin Has Shown Advantages to Eradicate Helicobacter pylori ( H. pylori ), but Not for Penicillin‐Allergic Patients. It Is Recommended That Cefuroxime Could Be an Alternative, but Whether Cefuroxime Could Be Used in Dual Therapy Has Not Been Reported. This Study Aimed to Compare the Efficacy, Safety, and Compliance of Cefuroxime‐Based Dual Therapy ( CDT ) With Cefuroxime‐Based Bismuth Quadruple Therapy ( CQT ) to Treat H. pylori Infection. Materials and Methods The Prospective, Multicenter, Open‐Label, Randomized Controlled Trial Was Conducted to Enroll Patients With Treatment‐Naive H. pylori Infection From 9 Institutions. Patients Were Randomly Assigned to CDT Group (Cefuroxime 500 Mg Three Times/Day and Vonoprazan 20 Mg Twice/Day) or CQT Group (Cefuroxime 500 Mg Twice/Day, Levofloxacin 500 Mg Once/Day, Vonoprazan 20 Mg Twice/Day, and Bismuth 220 Mg Twice/Day), both for 14 Days.

Results

700 Patients (350 per Group) Were Enrolled. In the Intention‐To‐Treat Analysis, Eradication Rates Were 76.0% and 86.3% in CDT Group and CQT Group ( P = 0.001). In the Modified Intention‐To‐Treat Analysis, Eradication Rates Were 78.9% and 89.1% ( P < 0.001). In the Per‐Protocol Analysis, Eradication Rates Were 80.2% and 91.2% ( P < 0.001). The Incidence of Adverse Events Was Significantly Lower in CDT Group Than CQT Group (14.4% vs. 29.8%, P < 0.001). Non‐inferiority Was Confirmed Between CDT and CQT Group (All P > 0.025). Compliance Was Good in Both Groups (96.0% vs. 92.8%, P = 0.073). Poor Adherence Was a Risk Factor for Reducing the Efficacy in Both Groups.

Conclusions

CQT Was More Effective Than CDT for H. pylori Eradication, Which Might Be Recommended for Penicillin‐Allergic Patients. If There Were Contraindications or Intolerance of CQT , CDT Would Be an Alternative. Trail Registration ChiCTR2300071210

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsAnti-Bacterial AgentsHelicobacter pyloriCefuroximeHumansMaleFemaleMiddle AgedDrug Therapy, CombinationProspective StudiesAdultBismuthTreatment OutcomeAgedLevofloxacinAmoxicillinPyrrolesSulfonamides

Stichwörter der Autor:innen

Helicobacter pyloribismuth quadruple therapycefuroximedual therapy

Substanzen

Anti-Bacterial AgentsCefuroximeBismuth1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineLevofloxacinAmoxicillinPyrrolesSulfonamides

Autor:innen und Institutionen

  • Division of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Gastroenterology, Chibi General Hospital, Chibi, China.
  • Department of Gastroenterology, Wuhan Third Hospital, Wuhan, China.
  • Department of Gastroenterology, The First People's Hospital of Tianmen, Tianmen, China.
  • Department of Gastroenterology, Wuhan Fourth Hospital, Wuhan, China.
  • Department of Gastroenterology, Wenchang People's Hospital, Wenchang, China.

ORCID-Profile: Ji-Yan Li, Zhen-Yu Zhang, Pei-Yuan Li

Förderung

  • Tongji Hospital Clinical Research Fund
  • Natural Science Foundation of Hainan Province
  • Hainan Province Science and Technology Special Fund
  • Natural Science Foundation of Hubei Provincial

Zitieren

APA

Li, J. Y., Song, J. C., Tian, X., Liu, Y. H., Ding, X. W., Lin, Y., Zhang, Z. Y., Zhang, H., Li, D. M., Huang, X. W., Hu, Y. L., Li, L., Li, H. T., Huang, C. Q., & Li, P. Y. (2025). Comparison of Cefuroxime‐Based Dual Therapy With Quadruple Therapy in Helicobacter pylori ‐Infected Treatment‐Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial. Helicobacter. https://doi.org/10.1111/hel.70037

Vancouver

Li JY, Song JC, Tian X, Liu YH, Ding XW, Lin Y, et al. Comparison of Cefuroxime‐Based Dual Therapy With Quadruple Therapy in Helicobacter pylori ‐Infected Treatment‐Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial. Helicobacter. 2025. doi:10.1111/hel.70037

BibTeX
@article{Li2025,
  author = {Li, Ji-Yan and Song, Ji-Chun and Tian, Xia and Liu, Yun-Hua and Ding, Xiang-Wu and Lin, Ya and Zhang, Zhen-Yu and Zhang, Hai and Li, De-Min and Huang, Xiao-Wei and Hu, Yun-Lian and Li, Li and Li, Hong-Tian and Huang, Chao-Qun and Li, Pei-Yuan},
  title = {Comparison of Cefuroxime‐Based Dual Therapy With Quadruple Therapy in Helicobacter pylori ‐Infected Treatment‐Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial},
  journal = {Helicobacter},
  year = {2025},
  doi = {10.1111/hel.70037}
}
Kostenlos starten →